Condition: Advanced Solid Tumor · Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd
Objectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes. Study Rationale: The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. Patient Population: Patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.
This description comes directly from the study's public registry record.
Yifan Xu · (+86)18516560587 · yifan.xu2@pharmaron.com
Weiyun Jia · (+86) 13810385484 · Weiyun.Jia@pharmaron.com
Always discuss trial participation with your own doctor first.
| Guangdong Clifford Hospital | Guangzhou, Guangdong, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare | New Taipei City, Taiwan | Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05103345